/
LUCD
$1.05-$0.03 (-2.78%)live
Held · Bookmarked
0 · 0
portfolios · users
Avg position size
—
of holders' portfolios
13F filers
1
institution
Market cap
$206.0M
191M shares
52-week range
$0.90 – $1.63
21% from low
Sector
SURGICAL & MEDICAL INSTRUMENTS & APPARATUS
Exchange
NASDAQ
CS
Borrow rate
0.57%
Easy to borrow
Price (6 mo)
Loading chart…
Change$-10.71
Valuation
Financials
Loading chart…
Click rows below (any statement) to add/remove series. Selection stays as you switch tabs.
| 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $500.0K | $377.0K | $2.4M | $4.3M | $4.7M |
| Cost of revenue | $0 | $0 | $0 | $585.0K | $3.6M | $8.5M | $8.3M | $7.5M |
| Gross profit | $0 | $0 | $0 | −$85.0K | −$3.2M | −$6.0M | −$3.9M | −$2.8M |
| Gross margin | — | — | — | -17.0% | -858.6% | -249.2% | -90.2% | -60.3% |
| R&D | $715.6K | $3.5M | $5.4M | $9.3M | $11.5M | $7.3M | $6.0M | $5.68B |
| Operating income | −$1.1M | −$4.4M | −$8.3M | −$27.4M | −$56.2M | −$48.5M | −$46.1M | −$49.6M |
| EBITDA | $563.0K | $0 | $482 | −$27.4M | −$54.2M | −$49.8M | −$44.3M | −$57.1M |
| Net income | −$1.1M | −$4.4M | −$8.3M | −$28.1M | −$56.2M | −$52.7M | −$45.5M | −$58.0M |
| Net margin | — | — | — | -5615.6% | -14899.5% | -2169.1% | -1047.6% | -1232.7% |
| EPS (diluted) | -0.03 | -0.12 | -0.22 | -0.78 | -1.55 | -1.26 | -1.05 | -0.69 |
Annual figures · source: Financial Modeling Prep
Analyst estimates (consensus)
| Year | Est. revenue | Est. EPS | EPS range | # Analysts |
|---|---|---|---|---|
| 2026 | $7M | $-0.24 | $-0.37–$-0.16 | 2 |
| 2027 | $20M | $-0.17 | $-0.27–$-0.12 | 3 |
| 2028 | $29M | $-0.15 | $-0.17–$-0.13 | 2 |
| 2029 | $35M | $-0.12 | $-0.19–$-0.08 | 1 |
Forward consensus · source: Financial Modeling Prep
Peer comparison
Lucid Diagnostics Inc. Common Stock
Lucid Diagnostics Inc is a commercial-stage medical diagnostics technology company focused on the millions of patients with gastroesophageal reflux disease (GERD), also known as chronic heartburn, acid reflux, or simply reflux, who are at risk of developing esophageal precancer and cancer, specifically lethal esophageal adenocarcinoma. Its products include EsoCheck and EsoGuard.
www.luciddx.com- Employees
- 82
- IPO / List date
- Oct 14, 2021
- HQ
- NEW YORK, NY
Held by traders on TradeandTell
No one on the platform currently holds LUCD.
Super investors & insiders
Institutions holding (13F)
| Institution | Shares | Reported |
|---|---|---|
| Renaissance Technologiesas of 2026-03-31 | 499,661 | $574.6K |
Insider activity (SEC Form 4)
Recent trades on TradeandTell
No one on the platform has traded LUCD yet.
